LobbyingEnanta Pharmaceuticals lobbying by quarter
Enanta Pharmaceuticals ENTA's latest lobbying report covers Q2 2024, at under $5,000. Its first report covers Q3 2023; the issues it reports most are Health Issues.
Enanta PharmaceuticalsENTA
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q3 2023
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2023 | $20K | 1 |
| Q4 2023 | $0 | 1 |
| Q1 2024 | $0 | 1 |
| Q2 2024 | $0 | 1 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$20K · 4 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- SENATE4 reports
Firms it paid
| Firm | ||
|---|---|---|
| Slaiman Consulting | $20K | 4 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/11/18for Q2 2024 | Slaiman Consulting | Under $5,000 |
| 24/07/02for Q2 2024 | Slaiman Consulting | Under $5,000 |
| 24/06/30for Q2 2024 | Slaiman Consulting | Under $5,000 |
| 24/04/16for Q1 2024 | Slaiman Consulting | Under $5,000 |
| 24/01/04for Q4 2023 | Slaiman Consulting | Under $5,000 |
| 23/11/14for Q3 2023 | Slaiman Consulting | $20K |
| 23/10/07for Q3 2023 | Slaiman Consulting | $20K |
| 23/09/28for Q3 2023 | Slaiman Consulting | Under $5,000 |